Produktanfrage
Asset Licensing Opportunity
Resources
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| CM-101 (ChemomAb) | CM-101 | Phase 2 Clinical | Chemomab Therapeutics Ltd | Metabolic Dysfunction-Associated Steatotic Liver Disease; Scleroderma, Systemic; Cholangitis, Sclerosing | Details |
Customer Reviews